Recent News

    
  • Immunis Chairman Dr. Hans Keirstead Recognized as a Top Orange County Business Leader

    Immunis, Inc., a private biotech company generating a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., was recognized as one of Orange County Business Journal’s OC 500, a list that includes the most influential individuals in Orange County. Honorees are selected on a merit basis after extensive evaluation and include top executives, government figures, philanthropists, and other civic representatives who contribute to the community of business.

  • CBS2 News Highlights Mission Plasticos, A Non-profit Providing Free Reconstructive Surgery to Underserved Populations [video]

    Immunis Chairman, Dr. Hans Keirstead, is the Board Chair of Mission Plasticos. Mission Plasticos is a non profit providing FREE reconstructive surgery to underserved populations in medical need. Please check out the segment from CBS2 News highlighting the importance of this life-changing work!

  • Immunis Chairman Dr. Hans Keirstead Presents at the Rejuvenation Startup Summit in Berlin [photos]

    Immunis Inc Chairman, Dr. Hans Keirstead, delivered an exciting presentation about the potential of IMM01-STEM at the 2022 Rejuvenation Startup Summit in Berlin, Germany. The Immunis team is thrilled to share the following images of Dr. Keirstead in action.

  • Immunis Chairman Dr. Hans Keirstead to Present at the Festival of Biologics Conference in Basel, Switzerland

    Immunis, Inc., a private biotech company creating an innovative treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will deliver the keynote address at the Festival of Biologics Conference in Basel, Switzerland. The Festival of Biologics is one of the leading international events for drug discovery, development, manufacturing, pricing and market access for clinical trials.

  • Immunis Chairman Dr. Hans Keirstead to Deliver Keynote at the Aging and Gerontology Conference in Dubai

    Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will present the keynote address at the Aging and Gerontology Conference in Dubai. The Aging and Gerontology Conference is a renowned international event that brings together longevity entrepreneurs, pharma and biotech companies, investors, researchers, and government organizations with the goal of extending human health span.

  • Immunis Chairman Dr. Hans Keirstead to Present at the Rejuvenation Startup Summit in Berlin

    Immunis, Inc., a private biotech company producing a novel treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will deliver a presentation on the main stage at the 2022 Rejuvenation Startup Summit (RSS) in Berlin, Germany. The Rejuvenation Startup Summit is a leading networking event for translational researchers, rejuvenation startups and longevity investors.

  • Immunis Chairman Dr. Hans Keirstead Presents United Nations General Assembly Keynote on Behalf of the National Institute of Child Sexual Assault [photo]

    Immunis, Inc., a private biotech company generating an innovative treatment for age and disease-related immune decline, announces that its Chairman, Dr. Hans Keirstead, delivered a keynote on behalf of the National Institute of Child Sexual Assault (NICSA) at the UN General Assembly in New York City. As part of Immunis’ ongoing Corporate Social Responsibility Program, Dr. Keirstead presented a keynote on child sexual assault (CSA), which aligns with the United Nation’s efforts to eradicate human trafficking and eliminate emotional, economical and physical violence against children and women.

  • Immunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board

    Immunis Inc., a private biotechnology company developing an immunomodulatory secretome for age and disease-related immune decline in Phase 1/2a testing, welcomes Peter H. Diamandis, M.D. to the Executive Advisory Board. Dr. Diamandis received degrees in molecular genetics and aerospace engineering from MIT and is a Harvard-trained physician. His entrepreneurship has led to the creation of over 25 companies in the areas of space, education, venture capital and longevity.

  • Immunis Chairman Dr. Hans Keirstead Presents Keynote Address at the United Nations “AI for Good” Global Summit

    Immunis, Inc., a private biotech company producing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., delivered a keynote to the United Nations (UN) as part of the AI for Good Global Summit. AI for Good is a digital platform helping innovators become educated in building and identifying practical AI solutions for the advancement of the UN’s “Sustainable Development Goals.”

  • Immunis Chairman Dr. Hans Keirstead Is Awarded Innovator of the Year [photo]

    Immunis, Inc., a private biotech company developing a novel immunomodulatory secretome for age and disease-related immune degeneration, congratulates its Chairman, Hans Keirstead, Ph.D., on being recognized as the Orange County Business Journal’s 2022 Innovator of the Year. This annual award highlights the greatest innovators of Orange County who have generated groundbreaking products, treatments, services and business models.

  • Immunis Initiates Patient Enrollment for Muscle Atrophy Phase 1/2a Clinical Trial

    Immunis Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, initiates patient enrollment for their Phase 1/2a clinical trial to assess Immunis’ immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy. Up to 18 patients ages 50-75 will participate in the clinical trial conducted at the University of California Irvine Medical Center, UCI Health, a facet of the California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network.

  • Immunis Signs Clinical Trial Agreement with CIRM Alpha Stem Cell Clinics

     Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has formally signed a clinical trial agreement with California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase 1/2a clinical trials. The trials will assess the safety and tolerability of Immunis’ immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy related to knee osteoarthritis, an inflammatory disease that is a leading cause of disability in elderly adults.

  • Immunis Publishes Research Study Showing Reversal of Aged Muscle Deficits

    Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, announced today the peer-reviewed publication of a research study conducted by Professor Micah J. Drummond at the University of Utah investigating the efficacy of Immunis’ immunomodulatory secretome product on aged skeletal muscle. The results were described in a GeroScience publication entitled “Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secretome product derived from partially differentiated human pluripotent stem cells.”

  • Immunis Announces FDA Clearance and Clinical Site for Phase 1/2a Clinical Trial Investigating Muscle Atrophy

    Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, today announced that the U.S. Food and Drug Administration has approved it’s Investigational New Drug application for a Phase 1/2a clinical trial investigating IMM01-STEM in participants with muscle atrophy: https://clinicaltrials.gov/ct2/show/NCT05211986

  • Immunis Closes $10 Million Financing Round

    Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has closed a $10M Series A First Closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Strategic investor, Continuum Health Ventures, which supports thesis-driven startups at the intersection of health and technology in the digital health and longevity sectors, also joined the round. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy, which is an age, disuse and disease-associated condition experienced by 100% of the population.

  • May 2022 FDA awards Phase 1/2a clinical trial to study the effects of Immunis’ platform immunomodulatory product STEM on muscular atrophy in patients with knee osteoarthritis